Skip to main navigation
Skip to search
Skip to main content
Arizona Board of Regents Home
Search content at Arizona Board of Regents
Home
Profiles
Departments and Centers
Scholarly Works
Grants
Activities
Equipment
Datasets
Press/Media
Prizes
Ipilimumab granulomatous interstitial nephritis
Bijin Thajudeen
, Machaiah Madhrira
, Erika Bracamonte
, Lee D. Cranmer
Research output
:
Contribution to journal
›
Article
›
peer-review
66
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ipilimumab granulomatous interstitial nephritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ipilimumab
100%
Granulomatous Interstitial Nephritis
100%
Renal Failure
50%
Metastatic Melanoma
33%
Renal Biopsy
33%
Renal Function Improvement
33%
Hepatitis
16%
First-ever
16%
Drug Use
16%
Young Males
16%
Temporal Relations
16%
Rash
16%
Chronic Kidney Disease
16%
Colitis
16%
T Cell Immune Response
16%
Skin Rash
16%
Male Patients
16%
Granuloma
16%
Renal Function
16%
Elevated Liver Enzymes
16%
Acute Renal Failure
16%
Drug-induced Acute Interstitial Nephritis
16%
Immune-related Adverse Reactions
16%
Common Side Effects
16%
Interstitial Nephritis
16%
Medicine and Dentistry
Ipilimumab
100%
Granulomatosis
100%
Interstitial Nephritis
100%
Kidney Function
50%
Renal Failure
50%
Exanthem
33%
Metastatic Melanoma
33%
Renal Biopsy
33%
Cellular Immunity
16%
T Cell
16%
Adverse Drug Reaction
16%
Acute Kidney Injury
16%
Chronic Kidney Disease
16%
Colitis
16%
Hepatitis
16%
Elevated Transaminases
16%
Granuloma
16%
Side Effect
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ipilimumab
100%
Granulomatosis
100%
Interstitial Nephritis
100%
Kidney Failure
50%
Rash
33%
Metastatic Melanoma
33%
Adverse Drug Reaction
16%
Chronic Kidney Failure
16%
Colitis
16%
Hepatitis
16%
Granuloma
16%
Hypertransaminasemia
16%
Acute Kidney Failure
16%
Steroids
16%
Side Effect
16%